An Unexpected Major Circulating Metabolite M219 Detected in 14C-labeled Human ADME Study of Brilaroxazine

At Frontage Laboratories, a systematic method development approach has been established by continuous monitoring of radioactivity at different study stages, such as in-life mass balance, sample extraction, and column recovery.

"*" indicates required fields

Company

This field is for validation purposes and should be left unchanged.

First Name*

Last Name*

Company*

State*

Country

Email*

Phone*

Please only hit the submit button once.

I AGREE*

By submitting this form I agree that Frontage may process my data in the manner described in Frontage’s Privacy Policy.

An Unexpected Major Circulating Metabolite M219 Detected in 14C-labeled Human ADME Study of Brilaroxazine

Resources to Consider

Identification of the Major Circulating Metabolite of Mymd-1 And...

AACR 2024: Analytical validation of a complete system for detection...

An Ultrasensitive LC-APPI-MS/MS Method for Simultaneous Determination...

Development and validation of LC-MS/MS methods for the quantification...

Determination of Fluticasone Propionate and Fluticasone...

Metabolites in Safety Testing (MIST): Analytical Strategy

Accurate Mass: The best solution for metabolite identification in...

Genotoxic Potential of Benzo[b]Fluoranthene (B[b]F):A Probable Human...

WRIB 2025: Validation of an Ultra-High Sensitive Simoa Assay for the...

WRIB 2025: Innovative Strategy for Overcoming pH-Related Assay...

IN Vitro Assessment of the inhibition of Human Organic Anion...

Cost Effective and Efficient Progression of Lead Drug Candidates to...